Yoshiaki Isobe
Dainippon Sumitomo Pharma Co., Ltd.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yoshiaki Isobe.
ACS Medicinal Chemistry Letters | 2014
Shingo Tojo; Tetsuya Kohno; Tomoyuki Tanaka; Seiji Kamioka; Takayuki Ishii; Keiko Kamimoto; Shigehiro Asano; Yoshiaki Isobe
Indoleamine 2,3-dioxygenase 1 (IDO1) is considered as a promising target for the treatment of several diseases, including neurological disorders and cancer. We report here the crystal structures of two IDO1/IDO1 inhibitor complexes, one of which shows that Amg-1 is directly bound to the heme iron of IDO1 with a clear induced fit. We also describe the identification and preliminary optimization of imidazothiazole derivatives as novel IDO1 inhibitors. Using our crystal structure information and structure-activity relationships (SAR) at the pocket-B of IDO1, we found a series of urea derivatives as potent IDO1 inhibitors and revealed that generation of an induced fit and the resulting interaction with Phe226 and Arg231 are essential for potent IDO1 inhibitory activity. The results of this study are very valuable for understanding the mechanism of IDO1 activation, which is very important for structure-based drug design (SBDD) to discover potent IDO1 inhibitors.
Bioorganic & Medicinal Chemistry Letters | 2013
Tomoaki Nakamura; Hiroki Wada; Hirotaka Kurebayashi; Tom McInally; Roger Victor Bonnert; Yoshiaki Isobe
We report the discovery of novel series of highly potent TLR7 agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety. The introduction of the amino group resulted in not only improved water solubility but also enhanced TLR7 agonistic activity. In particular compound 20 (DSR-6434) indicated an optimal balance between the agonistic potency and high water solubility. It also demonstrated a strong antitumor effect in vivo by intravenous administration in a tumor bearing mice model.
Bioorganic & Medicinal Chemistry Letters | 2010
Shigehiro Asano; Masafumi Komiya; Nobuyuki Koike; Erina Koga; Shogo Nakatani; Yoshiaki Isobe
A novel series of 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidines containing substituted phenyl sulfonamide are synthesized and evaluated for their inhibitory activity against CaMKII. Substituents on the phenyl group had significant impact on CaMKII inhibition, in particular, the inhibitory activity of 8p was 25-fold higher than that of KN-93, a known CaMKII inhibitor. Michaelis-Menten analysis of a representative compound suggested that the synthesized pyrimidines are calmodulin non-competitive inhibitors. Finally, 8p exhibited more than 100-fold higher selectivity for CaMKII over five types of off-target kinases.
Bioorganic & Medicinal Chemistry | 2011
Katsumi Kubota; Hirotaka Kurebayashi; Hirotaka Miyachi; Masanori Tobe; Masako Onishi; Yoshiaki Isobe
A series of tricyclic carboxylic acids having 6-amino-pyrimidine-2,4(1H,3H)-dione with piperazino or homopiperazino moiety linked by propylene, were synthesized and evaluated for their affinity toward human histamine H(1) receptor and Caco-2 cell permeability. Selected compounds were further evaluated for their oral anti-histaminic activity in mice, bioavailability in rats, and their anti-inflammatory activity in mice OVA-induced biphasic cutaneous reaction model. Among the compounds tested, dibenzoxazepine carboxylic acid 13b showed both histamine H(1) receptor antagonistic activity and anti-inflammatory activity in vivo. In addition, 13b exhibited low affinity toward α(1) receptor and low occupancy of H(1) receptor in the brain. It is therefore, believed that 13b is a potential candidate for development as 3rd generation anti-histamine.
Bioorganic & Medicinal Chemistry | 2012
Masafumi Komiya; Shigehiro Asano; Nobuyuki Koike; Erina Koga; Jun-etsu Igarashi; Shogo Nakatani; Yoshiaki Isobe
Based on 2-(4-phenoxybenzoyl)-5-hydroxyindole (2), a novel structural class of CaMKII inhibitors were synthesized and further optimized. The strong acidity of the hydroxyl group and the lipophilic group at the 4 and 6-positions were found to be necessary for strong CaMKII inhibition. Compound 25 was identified as a promising compound with 50-fold more potent inhibitory activity for CaMKII than 2. Compound 25 also showed high selectivity for CaMKII over off-target kinases.
Bioorganic & Medicinal Chemistry Letters | 2011
Masafumi Komiya; Shigehiro Asano; Nobuyuki Koike; Erina Koga; Jun-etsu Igarashi; Shogo Nakatani; Yoshiaki Isobe
A series of novel 2-substituted-5-hydroxyindoles were synthesized and evaluated for their inhibitory activity against CaMKII. Structure and activity relationship results indicated that potent inhibitory activity could be achieved by modification at the para-position of the phenyl ring of the high throughput screening hit compound 2. Among the prepared compounds, we identified 14 as a novel CaMKII inhibitor with an activity stronger than that of KN-93, a known CaMKII inhibitor.
Archive | 2006
Yoshiaki Isobe; Tomoaki Nakamura
Archive | 2003
Yoshiaki Isobe; Haruo Takaku; Haruhisa Ogita; Masanori Tobe; Ayumu Kurimoto; Tetsuhiro Ogino; Hitoshi Fujita
Archive | 2005
Haruhisa Ogita; Tomoaki Nakamura; Yoshiaki Isobe; Kazuki Hashimoto; Ayumu Kurimoto
Archive | 2003
Yoshiaki Isobe; Haruo Takaku; Haruhisa Ogita; Masanori Tobe; Ayumu Kurimoto; Tetsuhiro Ogino; Hitoshi Fujita